Study:
A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining
Rationale:
Celecoxib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of
cancer cells and slow the growth of kidney cancer. Giving celecoxib together with
recombinant interferon alpha-2b may kill more tumor cells and be an effective treatment for
metastatic kidney cancer.
Purpose:
This phase II trial is studying how well giving celecoxib together with recombinant
interferon alfa-2b works in treating patients with metastatic kidney cancer who have
undergone surgery.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Renal Cell Cancer
Stage IV Renal Cell Cancer |
Drug: celecoxib
Biological: recombinant interferon alfa-2b
Other: polymerase chain reaction
Other: laboratory biomarker analysis
Other: reverse transcriptase-polymerase chain reaction
Other: immunologic technique
Other: immunohistochemistry staining method
Other: flow cytometry |
Phase 2 |
Verified by
Case Comprehensive Cancer Center
August, 2012
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT01158534
Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Brian Rini., Principal Investigator